Literature DB >> 3128811

The selective dopamine antagonist properties of BRL 34778: a novel substituted benzamide.

F Brown1, W Campbell, M S Clark, D S Graves, M S Hadley, J Hatcher, P Mitchell, P Needham, G Riley, J Semple.   

Abstract

BRL 34778, exo-4-amino-5-chloro-2-methoxy-N-[9-(4-fluorophenylmethyl)-9-azabi cyclo(3.3.1) non-3-yl]-benzamide, is a very potent and specific dopamine D2-receptor antagonist. It exhibits a Ki value of 2.14 nM for dopamine D2-receptors but much lower affinity for D1-(Ki 5700 nM) and for many other receptor types. Its action is potent and of long duration in models for antipsychotic activity (4 h ED50s PO are 0.017 mg/kg for antagonism of apomorphine-induced climbing in mice and 0.028 mg/kg for antagonism of amphetamine-induced locomotion in rats). In contrast to its high potency in models for antipsychotic activity, BRL 34778 is much weaker in models for extrapyramidal effects and sedation (4 h ED50s PO are 2.4 mg/kg for inducing catalepsy in rats and 1.14 mg/kg for inhibition of rearing behaviour in rats). These data indicate potent activity of BRL 34778 in models for antipsychotic activity but low activity in models for extrapyramidal effects and sedation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3128811     DOI: 10.1007/bf00174689

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  37 in total

1.  Sulpiride versus haloperidol in schizophrenia: a double-blind comparative trial.

Authors:  G B Cassano; P Castrogiovanni; L Conti; L Bonollo
Journal:  Curr Ther Res Clin Exp       Date:  1975-02

2.  Is there a relationship between the involvement of extrapyramidal and mesolimbic brain areas with the cataleptic action of neuroleptic agents and their clinical antipsychotic effect?

Authors:  B Costall; R J Naylor
Journal:  Psychopharmacologia       Date:  1973

3.  Learning in tolerance to haloperidol-induced catalepsy.

Authors:  R E Hinson; C X Poulos; W L Thomas
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1982       Impact factor: 5.067

4.  A behavioural and biochemical comparison of dopamine receptor blockade produced by haloperidol with that produced by substituted benzamide drugs.

Authors:  P Jenner; A Clow; C Reavill; A Theodorou; C D Marsden
Journal:  Life Sci       Date:  1978-08-14       Impact factor: 5.037

5.  Catatonic behavior induced by haloperidol, increased by retesting and elicited without drug in rats.

Authors:  L F de Sousa Moreira; M C Pinheiro; J Masur
Journal:  Pharmacology       Date:  1982       Impact factor: 2.547

6.  Regional rat brain levels of 3,4-dihydroxyphenylacetic acid and homovanillic acid: concurrent fluorometric measurement and influence of drugs.

Authors:  B H Westerink; J Korf
Journal:  Eur J Pharmacol       Date:  1976-08       Impact factor: 4.432

7.  Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade.

Authors:  J Arnt
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1982-10

8.  Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain.

Authors:  S O Ogren; H Hall; C Köhler; O Magnusson; L O Lindbom; K Angeby; L Florvall
Journal:  Eur J Pharmacol       Date:  1984-07-20       Impact factor: 4.432

9.  Potent lipophilic substituted benzamide drugs are not selective D-1 dopamine receptor antagonists in the rat.

Authors:  S Fleminger; H van de Waterbeemd; N M Rupniak; C Reavill; B Testa; P Jenner; C D Marsden
Journal:  J Pharm Pharmacol       Date:  1983-06       Impact factor: 3.765

10.  Neuropharmacological profile of MD 790501, a new benzamide derivative.

Authors:  M Jalfre; B Bucher; N Dorme; G Mocquet; R D Porsolt
Journal:  Arch Int Pharmacodyn Ther       Date:  1983-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.